UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):June 18, 2014
DICERNA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-36281 | 20-5993609 | ||
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
480 Arsenal Street
Building 1, Suite 120
Watertown, Massachusetts 02472
(Address of principal executive offices, including zip code)
(617) 621-8097
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.07 | Submission of Matters to a Vote of Security Holders |
At the Company’s 2014 Annual Meeting of Stockholders held on June 18, 2014 (the “Annual Meeting”), the following actions were taken. The proposals below are described in detail in the Company’s definitive proxy statement dated April 30, 2014 for the Annual Meeting.
Proposal No. 1
The nominees for election as directors, each for a one year term, were elected based upon the following vote:
Nominee | For | Against | Abstain | Broker Non-Votes | ||||
Douglas M. Fambrough, III, Ph.D. | 15,513,752 | 300 | — | 500,754 | ||||
Brian K. Halak, Ph.D. | 15,513,752 | 300 | — | 500,754 | ||||
Stephen J. Hoffman, M.D., Ph.D. | 15,513,752 | 300 | — | 500,754 | ||||
Peter Kolchinsky, Ph.D. | 14,843,246 | 670,806 | — | 500,754 | ||||
Dennis H. Langer, M.D., J.D. | 15,480,752 | 33,300 | — | 500,754 | ||||
David M. Madden | 15,511,051 | 3,001 | — | 500,754 | ||||
Vincent J. Miles, Ph.D. | 15,511,051 | 3,001 | — | 500,754 |
Proposal No. 2
The proposal to ratify the appointment of Deloitte & Touche as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014 was approved based upon the following votes:
For | Against | Abstain | ||
| 16,014,357 | — | 449 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DICERNA PHARMACEUTICALS, INC. | ||||||
| Date: June 19, 2014 | By: | /s/ James E. Dentzer | ||||
James E. Dentzer Chief Financial Officer | ||||||